Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Leuplin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Leuplin is a drug for the treatment of prostate cancer. It is a sustained-release injectable formulation of leuprorelin acetate… 
2017
2017
The adult height of children with early onset puberty is limited by the premature maturation of hypothalamic-pituitary-gonadal… 
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2016
2016
OBJECTIVE The standard dose of depot gonadotropin releasing hormone agonist (GnRHa) may be too much to prevent premature… 
  • figure 1
  • figure 2
  • table 1
2007
2007
To reduce chemotherapy induced gonadotoxicity, co-treatment with gonadotropin releasing hormone against analogue (GnRHa) was… 
  • table 1
  • figure 3
  • figure 1
  • figure 2
2006
2006
Objective Recently, skin reactions to luteinizing hormone-releasing hormone (LH-RH) agonist therapy were reported after the 3… 
  • table 1
  • table 3
2006
2006
OBJECTIVE To investigate the change in volume of uterine fibroids after GnRH analog (GnRHa) treatment. MATERIALS AND METHODS… 
2003
2003
OBJECTIVES To assess the involvement of calcitonin gene-related peptide (CGRP) in the occurrence of hot flashes in men after… 
2003
2003
This study aimed to examine the activation of poly(ADP-ribose) polymerase (PARP) and the accumulation of its end product, poly… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2002
2002
GnRH agonist (GnRH-a) therapy is known to shrink uterine leiomyoma, although the molecular mechanisms responsible for this effect… 
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
2001
2001
BACKGROUND/PURPOSE Twenty-two institutes have organized Keio University Prostate Cancer Study Group to study clinical efficacy…